The traditional method for detecting equine lameness is subjective, using expert visual evaluation of gait to identify the presence or absence and degree of asymmetries. The lame horse is described as having a disorder, defect or loss of function and this clinical diagnosis has associated welfare implications if the horse is still asked to perform.
The article explains how advanced computer technology is starting to change all this. Optic motion capture or the use of inertial measurement units (IMUs) is now enabling the detailed study and quantification of the horse’s gait; objective assessment against preset thresholds. The paper points out that while these digital systems can overcome the temporal and spatial limitations of the human eye they simply rely on one or a number of set gait parameters to decide about lameness and this can present obstacles.
Thresholds are forcibly based on a limited reference population, which doesn’t adequately reflect the millions of horses in the world. The individual environmental and mental conditions for each horse and its day-to-day gait variations are also not accounted for. On this basis to use the term ‘lame’ because a horse demonstrates a subtle gait alteration, causing it to fall below the threshold, could be inappropriate, particularly as it may not affect the horse’s welfare in any way.
Professor Celia Marr, Editor of the Equine Veterinary Journal said: "An important first step is for researchers and clinicians to start to discriminate clearly between 'asymmetry' and 'lameness' and not to use these as interchangeable terms when interpreting gait analysis data. Asymmetry is often, but not always, a hallmark of lameness, but is not a clinical term, whereas lameness is."
The programme starts at 9:00am on the 1st April with a keynote address by Professor Iain Chapple, Head of the Birmingham Dental School, and then spits into two streams, one for beginners, the other for advanced practitioners.
The beginners stream includes: 'Clinical examination and charting - a logical approach' and 'Malocclusions and Surgical extraction technique and complications', whilst the advanced stream includes: 'Canine Chronic Ulcerative Stomatitis', 'What are the Hidden Dangers in your Dental Unit?' and 'Case based Periodontal/ Gingival Histopathology'.
The BVDA Scientific Programme costs £140, and you can register here: https://www.bvda.co.uk/bvda/registersm
However, as BVDA President Paul Cooper MRCVS (pictured right) was keen to point out: "It does work out cheaper to join the BVDA and then get the member discount for the Scientific Programme!"
On the 2nd April, the association will also be running two drylab practical sessions (using models, not cadavers).
The first, with Tom Williams BVSc MANZCVS (Small Animal Dentistry and Oral Surgery) MRCVS and Megan Clark BDS (Hons) Bsc (Hons) AKC offers a practical overview of root canal treatment.
The second, with Alix Freeman BVSc MRCVS and Andrew Perry BVSc DipEVDC MRCVS offers an introduction to composites and non-invasive jaw fracture repair.
Each drylab costs £100, and registration is via the BSAVA Congress registration page: www.bsavaevents.com.
In the last four years, there has been an increase in the number of identified B. canis cases in the UK, which had previously been sporadic and isolated.
Data released by the Government shows that cases have risen from three reported before 2020 to 240 in the last three years.
Most dogs were either imported, had returned from holiday overseas, or been bred with an imported dog.
In 2022, the first UK case of dog-to-human transmission was reported, highlighting the risks to those handling and treating infected dogs and raising levels of concern within veterinary teams, although the BVA says the risk is relatively low.
The BVA, SPVS and BVNA joint policy calls on the Government to :
British Veterinary Association President Anna Judson said: “Vets are seriously concerned about the lack of adequate checks for potentially zoonotic diseases entering the country via imported dogs.
"Brucella canis is not currently considered to be widespread in the UK, so a proactive approach with an emphasis on reducing the risk of this and other worrying exotic diseases being brought into the UK is crucial.
“This is important both for the health of the UK’s dogs and the humans who care for them."
https://www.bva.co.uk/take-action/our-policies/brucella-canis
Police have advised veterinary practices to be on their guard following a spate of break-ins in the South East, linked to the theft of controlled drugs.
PC Steve Doswell, Controlled Drugs Liaison Officer in the East Sussex police area said: "Criminal elements in the South East are targeting practices in Surrey, Hampshire and East Sussex. They may well have targeted, or will target, other practices in all of the neighbouring counties".
"Methadone, Ketamine, Alprazolam and Diazepam are all commonly-abused by drug users, and nationally there have been a lot of problems with users buying street heroin that has been cut with Alprazolam," he added.
PC Doswell offered the following advice to practices:
More detailed information about the correct storage of controlled drugs can be found in the RCVS Practice Standards Scheme Manual: www.rcvs.org.uk/practicestandards
The RCVS Trust has announced 34 grants totalling approximately £165,000, being made to veterinary surgeons, universities and higher education (HE) establishments, to fund high-quality research projects in the UK and overseas, and support veterinary education.
Harper Adams University College and Myerscough College will be the first veterinary nursing colleges to receive funding under the Spencer-Hill equipment grants programme; this was the first time that RCVS-approved HE veterinary nurse training providers were able to apply for this funding. Harper Adams will receive £2,350 to purchase a Humphrey ADE-circle system, and Myerscough, £1,395 for an 'Emily' canine positioning mannequin.
Severine Tasker MRCVS, from the University of Bristol, and Janet Patterson-Kane MRCVS, from the University of Glasgow each received Blue Sky Awards of £17,000. Severine will conduct research into constructing defined feline coronavirus strains for determination of the role of virus genetics in the development of feline infectious peritonitis. Janet Patterson-Kane's research will investigate whether a new therapy for treating wounds in humans can be translated for use in horses.
Janet said: "Limb wounds in horses are very common and are notorious for developing masses of exuberant scar tissue - proud flesh - and not healing properly. This can necessitate multiple operations. The findings of current research at University College London by our collaborator, Professor David Becker, suggest that in human patients a protein, connexin 43, is not downregulated at the edges of wounds that are difficult to heal. Use of therapy to reduce connexin 43 expression in human skin wounds in which healing has stalled has been remarkably successful in achieving wound closure. The aim of our research is to determine if connexin 43 plays a similar key role as a 'master switch' for wound healing in horses. I am extremely grateful to the RCVS Trust for their support."
Six veterinary undergraduates will also receive EMS vacation research scholarships of £700 each, which can be used to fund expenses relating to a research project undertaken in the UK or overseas as part of a UK veterinary school's extra-mural studies requirement.
Full details of the RCVS Trust grant awards may be found at www.rcvstrust.org.uk/awards
Europe's largest private specialist veterinary practice, Davies Veterinary Specialists, has opened a new centre at the premises of the Hyde Park Veterinary Centre in Connaught St., London W2.
Davies Veterinary Specialists employs 40 veterinary surgeons, 23 of them RCVS Recognised Specialists and more than 50 nurses. The main hospital, based in Bedfordshire, has sophisticated diagnostic, surgical and treatment facilities and offers integrated multi-disciplinary care.
Clive Elwood, Managing Director of DVS, said: "We believe that pet owners should have easy access to the top veterinary specialists in the country. We are now bringing a team of specialists offering consultations in medicine, cardiology, ultrasonography, neurology, ophthalmology, orthopaedic and soft tissue surgery to Davies London. This will make it much easier for London vets to offer their clients a convenient referral service, with full access to state-of-the-art facilities."
The Hyde Park Veterinary Centre is a long-established central London veterinary clinic. Recently expanded and refurbished, the clinic has invested heavily in the latest diagnostic and treatment facilities for the clinical care and treatment of London's pets. Head vet Andrew Prentis said: "We are all very excited about the collaboration with Davies: this new local access to top level specialists is really going to help London's vets offer their clients the very best in veterinary care at all times."
For more information, call 0207 535 0444 or visit www.vetspecialists.co.uk/london
HRH The Princess Royal has opened the Animal Health Trust's new cancer treatment and research facility in Suffolk.
The facility has been purpose-built to treat horses, dogs and cats with cancer. It will also assist in furthering understanding of the disease in animals.
Peter Webbon, Chief Executive of the AHT, said: "2012 marks 70 years of the AHT fighting disease and injury in animals, and the addition of the Cancer Centre is a landmark achievement in our history. We believe this is the first facility of its kind in Europe, purpose-built to treat horses, dogs and cats with cancer. We now have a short commissioning process to undertake but anticipate welcoming the first patients through the doors in early 2013."
The Kennel Club Cancer Centre at the AHT houses a linear accelerator (pictured right) and brachytherapy machine used in radiotherapy treatment, along with a 16-slice CT scanner to aid radiotherapy planning.
The new facility complements the AHT's existing cancer treatment options of surgery and chemotherapy meaning the Suffolk-based charity will be able to offer each and every patient the very best options for their specific case, whatever the diagnosis. With one in four dogs and one in six cats developing cancer at some time in their life the new centre will help many more animals fight cancer.
Peter Webbon, added: "It was thanks to a generous donation from the late Tom Scott, a long-term supporter of the AHT, that we were able to start this development. His donation, along with that from many other AHT supporters, and an interest-free loan of £1.5 million from the Kennel Club has meant this ambitious project has come to fruition so quickly."
It has taken just over a year to build the Cancer Centre which contains more than 2,600 tonnes of concrete and has eight-feet wide solid concrete walls.
On opening the facility, HRH The Princess Royal, President of the AHT, said: "This Cancer Centre is an exciting development at the AHT and will make a real difference for animals with cancer, here and now. It will improve the chances, for many animals, of beating this pernicious disease.
"Countless other horses, dogs and cats across the world with cancer, who will never be seen by an AHT clinician, will also benefit from knowledge gained from research in The Kennel Club Cancer Centre at the AHT."
The AHT has a strong history in cancer research and the Kennel Club Cancer Centre will enhance the charity's well established cancer research programme. Knowledge gained through the treatment of animals in the facility will contribute to the study of cancers, their causes, early diagnosis and treatment, and ultimately hopefully the prevention of some forms of the disease.
Steve Dean, Kennel Club Chairman, said: "I am very proud to be here today to celebrate the opening of the Kennel Club Cancer Centre. Thanks to the expertise available here at the Animal Health Trust, the Cancer Centre will provide advanced techniques for the diagnosis and treatment of cancer, to the benefit of many animals. It is exciting to consider how synergy between the Kennel Club Cancer Centre and the Kennel Club Genetics Centre can help to further the understanding of the inheritance factors that influence the development of cancer."
Vétoquinol - maker of Epiphen, the anti-epileptic phenobarbital for the control of epilepsy in dogs - has added a new client brochure and a fridge magnet to its Epiphen support packs, designed to help owners understand the condition and make it easier for them to comply with daily dosage requirements.
The new brochure is called What I need to know and is written for clients that have been prescribed Epiphen for their pet for the first time.
Abbie King, Product Manager for Epiphen, said: ''The inspiration for the new brochure came after spending time at the Animal Health Trust in Newmarket and realising how much information an owner needs to take in when their dog is diagnosed with epilepsy."
The new brochure covers the important information owners need to help them understand and manage their dog's epilepsy, including how Epiphen works, what they can do to help their dog, how to monitor seizures, where to find further information and frequently asked questions.
The Epiphen Treatment fridge magnet is designed as a quick reference guide to prescribing information that is needed every day when living with a dog with epilepsy. The magnet leaves space for the owner to write in their dog's name, dosage details and timings and their vet's phone number. Vétoquinol says it is especially helpful as a reference if more than one person is caring for the dog.
The new items enhance the existing Epiphen support pack, which comprises an owner manual, medication record and seizure diary, dog tags, seizure report pads, free serum level monitoring vouchers and a free, online resource at www.epiphenonline.co.uk
Vétoquinol also invites practitioners who are dealing with challenging cases to take advantage of its free Ask the expert scheme on 0800 169 8197 or email a case history to epiphen@vetoquinol.co.uk.
To order the new Epiphen support materials, ring 0800 1698197. Alternatively, visit: www.vetoquinol.co.uk to find out more.
The company has introduced a new online range of pack inserts for several of its key products including Vetoryl, Felimazole, Metrobactin and Thyforon so veterinary practices can download and print the latest pack inserts for the treatments.
The move will ensure that practices always have access to the most up-to-date information about the prescribed medication. Dechra says it will also save time as staff will not have to copy original documents from the pack.
The pack inserts will be available via www.dechra.co.uk and www.dechra.ie. In addition, Dechra has developed dispensing envelopes which are available at no charge from wholesalers in packs of 25.
Larry King, Marketing Manager, said: "Veterinary practices often dispense pharmaceuticals from bulk which involves having to copy original pack inserts for owners.
"By printing the online pack inserts, practices will no longer have piles of inserts to store and will be safe in the knowledge they are supplying the most up to date pack insert to their clients.
"When used together, the pack inserts and dispensing envelopes provide practices with an effective solution when dispensing from bulk."
Four separate studies are included in the collection, reporting novel risk factors for the disease, identifying key differences between EGS and botulism (questioning the hypothesis that EGS is caused by neurotoxins from Clostridium botulinum), reporting a novel diagnostic technique and showing the value of monitoring weight loss to help predict whether individual horses with chronic EGS are likely to survive.
The publishers say that despite more than 100 years of research, supported predominantly by the The Moredun Foundation Equine Grass Sickness Fund (www.grasssickness.org.uk), the cause of EGS remains unknown. Since it almost exclusively affects grazing horses, a pasture derived neurotoxin is implicated. EGS causes gut paralysis as a result of damage to parts of the nervous system that control involuntary functions. Acute and sub-acute EGS is invariably fatal while around 55% of chronic cases can survive and return to a useful working life. The UK has the highest incidence of EGS in the world; indeed it is estimated that the disease kills between 1 and 2% of horses in the United Kingdom annually. Cases are more common in spring.
In terms of risk factors, the study ‘Equine grass sickness in Scotland: A case-control study of environmental geochemical risk factors’ suggests that the high incidence of the disease in Eastern Scotland may be partly associated with the particular composition of macro and trace elements in the soil in the fields on which horses graze. Further work is required to determine whether interventions to alter concentrations of particular elements in soil could potentially reduce the risk of EGS.1
A second study identified key differences between EGS and botulism, which questions the currently favoured hypothesis that EGS is caused by neurotoxins from Clostridium botulinum, a bacterium which commonly inhabits soil. The study ‘Equine grass sickness, but not botulism, causes autonomic and enteric neurodegeneration and increases soluble N-ethylmaleimide-sensitive factor attachment receptor protein expression within neuronal perikarya’ suggests that EGS is unlikely to be caused by neurotoxins from this bacterium and concludes that further investigation of an alternative cause for EGS is needed.2
While the majority of horses with EGS can be readily diagnosed by experienced veterinary surgeons, some cases present a diagnostic challenge. Indeed the only way to definitively diagnose the disease in a live horse is to demonstrate the characteristic degeneration of nerves within biopsies of the intestine. Unfortunately these biopsies can only be collected by performing abdominal surgery under general anaesthesia. In the study ‘Neuronal chromatolysis in the subgemmal plexus of gustatory papillae in horses with grass sickness’ characteristic degeneration of nerves was identified in small biopsies collected from tongues of EGS horses during post mortem examination. Examination of these biopsies accurately differentiated control horses from EGS cases. While further validation of this technique is required, it could potentially provide a relatively non-invasive method of confirming the diagnosis in a live horse.3
While around 55% of horses with chronic EGS survive, objective criteria for predicting survival of these cases are currently lacking. The study ‘Bodyweight change aids prediction of survival in chronic equine grass sickness’ reported that non-survivors had greater rate and magnitude of bodyweight loss than survivors. Survival prediction curves were published to allow veterinary surgeons and horse owners to use body weight data to help determine whether an individual horse with chronic EGS was likely to survive or die.4
Professor Bruce McGorum, Head of the Equine Section at the Royal (Dick) School of Veterinary Studies & Roslin Institute in Edinburgh, has been leading much of the research. He said: "Given that our recent research suggests that EGS is unlikely to be caused by neurotoxins from Clostridium botulinum we are now moving on to determine whether EGS is caused by ingestion of mycotoxins produced by pasture fungi. We are very pleased that The Horse Trust (www.horsetrust.org.uk) has provided funding for this three-year investigation."
Professor Celia Marr, Editor of the Equine Veterinary Journal said: “While the cause of equine grass sickness continues to evade us, these papers present an optimistic step in the right direction for the eventual prevention of this dreadful disease. It is only with the support of the Moredun Foundation Equine Grass Sickness Fund and more recently that of The Horse Trust that our world-leading veterinary researchers are able to continue to unravel the mystery.”
The EVJ equine grass sickness collection can be downloaded at http://bit.ly/2dC7Drr
References
The two sets of guidance cover:
RCVS President Dr Mandisa Green said: “I would like to reassure my colleagues once again that we understand the extreme challenges and difficult decisions they are facing.
"The College has no interest in taking anyone to task for considered professional judgement, providing they act reasonably in the circumstances, can justify their actions and take reasonable notes.
"Sadly, we’re seeing the pandemic situation deteriorating again in the UK, but to varying degrees across the country. This presents a significant challenge in ensuring our guidance is clear and straightforward, while remaining relevant to as many people as possible.
"We sincerely hope this new guidance achieves that aim and supports veterinary professionals working to uphold animal health and welfare, while maintaining the safety of their teams and clients."
For more information, visit: https://www.rcvs.org.uk/setting-standards/advice-and-guidance/coronavirus-covid-19/
Open to everyone in the profession, Congress '24 will include over 130 hours of CPD across 32 different modules covering topics such as advanced diabetes, dermatology, nursing clinics, EDI and more.
The programme format caters to a variety of learning styles, from lectures and panel discussions to interactive sessions and free CPD workshops.
There'll be over 120 exhibitors in three commercial exhibition, offering insights into some of the latest industry innovations, from pharmaceuticals to cutting-edge equipment.
Andy Green, Chair of the Congress Committee said: "We know it's a significant commitment for individuals to give up one to three days, plus travel time, to join us, and we don't just aim to educate; we want our attendees to enjoy the experience.
"Our aspiration is not just to meet their expectations but to exceed them.
"The veterinary profession faces challenges, but we have so much to celebrate, and what better place to come together with many like-minded individuals to remind yourself why you wanted to be in this profession in the first place."
Early bird registration is open until 31st January, and prices start at £93 +VAT for BSAVA members for a one-day pass.
www.bsavacongress.com
CEVA Animal Health has extended its behavioural range of products with the launch of Senilife®, a nutritional supplement which is specifically formulated to help manage signs of brain ageing in dogs and cats.
Senilife® contains a combination of three essential brain nutrients - phosphatidylserine, vitamin B6 and vitamin E - which the company says help maintain membrane fluidity and normalise neurotransmission. In addition, two natural but potent anti-oxidants - gingko biloba and resveratrol - support brain metabolism and help to neutralise free radicals and reduce amyloid deposits.
According to CEVA, common signs of brain ageing in dogs and cats include playing or interacting less, barking or howling at night, loss of house-training/litter box training, apathy or increased tiredness and disorientation. A study has shown that up to 75% of dogs over seven years of age and 35% of cats 11 years and over suffer from at least one geriatric behavioural problem1.
In a recent clinical study, 86% of owners were satisfied with the results achieved after one month of using Senilife®, with 73% of dog owners and 67% of cat owners noticing fewer signs of brain ageing within the first seven days2.
Juliet Penaliggon, small animal marketing manager at CEVA Animal Health, says: "Many typical signs of brain ageing in dogs can be controlled by nutritional management. Senilife® is a fast-acting, nutritional supplement that contains proven nutrients and neuroprotectives to help manage these signs."Senilife® capsules are easy to administer either directly into the mouth of the pet or emptied onto the pet's food."
For further information, please contact your CEVA Animal Health representative or call 01494 781510.
References1 Behaviour problems in geriatric pets. Lansberg G and Araujo J. Vet Clin North Am Small Anim Pract. 35 (2005) 675-698.2 Isaka N, Baysse B, Lopez A, Ovaert P and Penaliggon J. CABSTG Spring Meeting April (2009).
BCF, the veterinary imaging company, has launched a competition in which you can test your knowledge on a series of x-ray and ultrasound images for the chance to win a Sony Cyber Shot digital camera.
Visit the BCF website to enter - www.bcftechnology.com/
Entries to be in by 31st May 2011 and the winner will be drawn at random on the 6th of June 2011.
Zoetis Business Consulting has announced the launch of Profitsolver, a software tool designed to boost practice profits.
The software has already been rolled out in the US, where Zoetis says that it has delivered an average of £103,000 extra profit to veterinary practices within a year.
Profitsolver uses the practice's actual data - not benchmarks or accepted norms - to enable the practice to manage costs, set prices and gain return on investments. By using an activity-based costing model and using a variety of data such as practice costs, which staff perform which part of the procedure, how long the procedure takes and what equipment and materials are used, Profitsolver calculates the correct pricing to both cover costs and deliver a predetermined profit margin.
Zoetis says that Profitsolver helps practices to understand how the overall practice profit is being generated. For instance, for price sensitive procedures such as vaccination, the practice can match their prices with the competition, but maintain their profit margin by increasing the price for other clinical services.
Nick Steele, national consulting manager at Zoetis said: "Veterinary practices have no standard method for pricing their services and they are often unable to determine which services make money and which don't. This hampers the practice's ability to accurately value the business and, as a result, profit levels tend to be low for many practices. Profitsolver can turn this situation around and already has a very successful track record in the US."
Zoetis piloted the UK version of Profitsolver with John Goulding at St Georges Veterinary Group. He said: "By and large the veterinary profession still relies on the mark-up of medicines where profits are concerned. Even practices that have made a concerted effort to move away from this type of pricing structure are still making their money from the sale of medicines rather than from vets' fees. For years I have wanted to know exactly how to price our services and this new Profitsolver software does just that.
"Most costs have an element of staff time, an element of fixed assets or equipment and an element of disposable items. Profitsolver takes all of these into account, adds the predetermined profit margin and produces an accurate pricing structure for each procedure undertaken within the practice.
"It's important to take the time at the start to put accurate data in from the practice's latest set of accounts and the Zoetis business consultant will guide practices through this to make the initial set up as easy as possible. For instance, for major pieces of equipment such as X-ray machines, you have to work out how many times a year you are likely to use them.
"By using Profitsolver, we worked out that if we do exactly the same amount of work as last year we can increase our bottom line by at least £200,000 for our 18 vet practice. Since last November, when we installed Profitsolver, we have completely changed our pricing structure moving away from focusing on medicines and the size of the animal to rethink how we charge our clinical care.
"An unexpected benefit is that Profitsolver has made me much more confident about the prices we charge to clients as it is all broken down, so we can see exactly how the invoice is made up. I would be at a loss without it now."
For more information about Profitsolver, contact your Zoetis account manager.
Dan (MRCVS) & Kirsty (RVN) Forster, the husband and wife team behind Isle of Wight-based The Mobile Vet are celebrating a Queen's Award for Enterprise.
The Mobile Vet offers a mobile service in custom-designed vehicles and also has a fully-equipped surgery based in Newport where further consultations, operations and diagnostics can be performed, giving clients the option to choose between a home visit or a more traditional form of veterinary care for their pets.
News of the award landed on their doormat recently, in a letter saying: "I am delighted to inform you that Her Majesty The Queen has been graciously pleased to approve the Prime Minister's recommendation that your organisation should receive a Queen's Award for Enterprise in Innovation this year."
The Queen announced the winners of the awards as part of her 90th birthday celebrations yesterday, and Kirsty & Dan have been invited to Buckingham Palace to meet her at an official reception in July.
Dan said: "We have been fortunate enough to receive excellent feedback from our clients since starting our business & enjoy an immense amount of job satisfaction with the way we work. A nod from Her Majesty is truly the crowning glory for our business. It just goes to show what can be achieved with exceptional hard work and effort, the love & support of family/friends & a formidable staff. This award is for all these people that help to make our business great!
"We are very much looking forward to meeting the Queen and can't quite get our heads round it. Kirsty has spent hours looking for a dress and I am brushing up on my royal etiquette!"
The kit contains a guide to effective ear cleaning, an illustrated step-by-step instruction guide on how to administer the Canaural, and a diary and consultation pack so owners can engage with the diagnosis and treatment of their pet’s ear infection.
The Healthy Ears Combi Kit comes in a resealable wipe-clean bag and is available free of charge from veterinary wholesalers.
Dechra Brand Manager Claire Morgan said: "The new kit will give owners more confidence in the important role that they play in their pet’s ear health and encourage them to engage in the treatment plan, thereby supporting veterinary professionals in the cycle of care.
"As well as serving as practical storage for the products, it acts as a reminder to dispense CleanAural as well as Canaural, as the self-cleaning mechanism of the animal’s ears is often compromised by infection.
She added: "CleanAural does not compromise the antimicrobial activity of Canaural1 so they are perfect partners for maintaining healthy ears."
Free Healthy Ears Combi Kit can be ordered via your veterinary wholesaler.
Reference
Sue, who is President of the European Society of Dermatology and an RCVS Specialist, says in a video interview that antimicrobial resistance (AMR) is making otitis externa cases difficult to resolve and that vets can help overcome the problem by rethinking their first line prescription choices.
In the video, created in conjunction with Elanco Animal Health (maker of Osurnia), Sue said: "It’s a sad thing to say but if everybody did manage cases of otitis externa appropriately first time, I probably wouldn’t have a job at all."
"Many of the cases I see as a referral clinician are longstanding cases with very severe, multiply-resistant infections. If we get these cases right on the first occasion with appropriate prescription of drugs, and we don’t hurt dogs so we can give ongoing treatment, then we’d never ever see pseudomonas infection again."
Sue believes part of the problem is that veterinary surgeons are incorrectly saving some of their best first-line treatments for difficult cases. This is perpetuating the antimicrobial resistance problem as cases are being inadvertently mismanaged.
She said: "Florfenicol, which is the active antibiotic in Osurnia, has excellent gram positive activity which makes it an ideal first line choice. However, there’s a misconception that florfenicol is a fluoroquinolone - which it isn’t - so vets are incorrectly ‘saving it’ rather than using it on the first occasion."
Sue also highlights that poor compliance, resulting from the patient’s behavioural problems associated with ear phobia, also has a long-term impact:
"We’ve seen many 'well behaved' dogs that have bitten their owners as a result of fear aggression; we’ve had dogs that have pinned their owners against the wall. I would argue very strongly that if you use long-acting products in dogs on the first occasion then you avoid creating that problem and these dogs don’t become difficult to medicate on a long-term basis."
Sue summarised two factors that vets need to consider when deciding on the appropriate treatment: the right active ingredients to target common first-line pathogens; and the method of application. She urged vets to consider using a long-acting product applied within the practice, removing the need for home treatment to reduce stress for both owner and the dog, improve long-term compliance and maximise clinical outcomes.
To hear Sue’s tips on how to treat cases of otitis, watch the video here – www.osurnia.co.uk
The BEVA Trust is the Association’s philanthropic arm and in 2015 members decided that it should provide support for voluntary projects to help improve knowledge and welfare.
Since then volunteers have been rolling up their sleeves to help out with castration and welfare clinics in the UK and veterinary training schemes around the world.
Over the past 12 months a total of 42 vets and vet nurses have volunteered their time at seven BHS Education and Welfare Clinics throughout the UK.
They have helped microchip, passport, vaccinate and castrate horses recognised by Welfare Officers as needing help.
So far 598 horses and ponies have received passports and 302 been castrated.
The Trust has seen a further ten volunteers travel across the globe, working on projects in Cambodia, the Gambia, Honduras, Kiev, Nicaragua and the Ukraine.
BEVA President Vicki Nicholls said: "We thank all of the volunteers that make our Trust such a success, with special mention to Luke Edwards from the University of Liverpool and Alice Horne from Ddole Road Veterinary Clinic who have both volunteered at four clinics. We must also remember the good work of our industrious BEVA Council members and our excellent speakers at Congress this September, who are all volunteers."
For further information on BEVA Trust volunteer projects email lara@beva.org.uk to be added to the BEVA Trust mailing list.
Vets Now says that the move to holding the 4 day congress online has resulted in a surge in interest from international delegates, with veterinary surgeons and nurses from more than 20 countries, including Kuwait, Hong Kong and Australia, due to attend.
Speakers at the event this year include Dan Fletcher, Megan Brashear and Claire Sharp.
Dan Lewis, Vets Now’s national ECC lead, said: “The interactive platform we’re using is cutting edge and it provides so much more than just webinars. There will be live content, an interactive exhibition hall and more opportunities than ever for delegates to network and learn from some of the world’s leading veterinary experts discussing emergency and critical care.
"Our programme this year has been carefully tailored to provide an inclusive learning experience for vets and vet nurses no matter what stage they’re at in their career, from students through to specialists.
"We’ll obviously miss seeing everyone in person, but we’re very excited that we can gather together online for a one-of-a-kind experience.”
Full four-day tickets for delegates range in price from £60 to £175 and ticket-holders will be able to access all the sessions on-demand for up to a month following the event.
Click here to book your place at Vets Now’s ECC Congress. Registrations close on November 1. To book your place, visit: congress.vets-now.com
MI:RNA says that current testing practices for Johne’s disease mean that identification of the disease is difficult, with current sensitivities of around 10-40% and little to no ability to diagnose early stages of infection.
The loss of productivity due to Johne’s to the UK agricultural economy is estimated to be in excess of £10 million annually.
MI:RNA says it is the first diagnostic testing company to use microRNA assay technology.
MicroRNAs are newly discovered biomarkers that manage the immune system and immune responses and act as regulators for disease progression or resolution.
This, says the company, makes them excellent biomarkers of disease, and when combined AI, can significantly improve identification of Johne’s and other complex conditions, and predict disease outcomes.
MI:RNA says this development will allow veterinary surgeons, farmers and pet owners to test for a variety of conditions, not just Johne’s.
Target areas include heart and kidney disease, osteoarthritis and bovine tuberculosis, along with effective general wellness and preoperative screening.
Eve Hanks, founder and CEO of MI:RNA, said: “Increasing market and global pressures on bovine protein production means that animal health has never been more important.
"This is a key area of research and development for MI:RNA and biomarker science combined with our unique AI-powered modelling, means that we can significantly improve animal health and reduce greenhouse gas output.
“The breakthrough that we’ve already achieved in Johne’s testing is unparalleled, and has provided an opportunity for MI:RNA to pitch our business concept in the USA to the The Kansas City Animal Health Summit.
"Following our presentation, we have now progressed through to the final selection stage for European Innovation Council funding for our work on Johne’s disease.
“In terms of future applications, microRNAs can assist with vital drug discovery, progressing future diagnostic testing and understanding disease pathways more effectively.
"We’ve already made remarkable progress and we know that with the continued backing of our tech, AI and health experts and with the correct funding, that we can do so much more.”
An international group of scientists has published new results that herald a breakthrough in finding a vaccine against the most commonly diagnosed infectious disease of horses, strangles.
UK experts from the Animal Health Trust collaborated with scientists from the Swedish University of Agricultural Sciences (SLU), the Karonlinska Institutet Medical University and Intervacc AB, on the project - the results of which could benefit humans as well as animals.
Professor Andrew Waller, Head of Bacteriology at the AHT, said: "We have been working towards developing a vaccine for 7 years, and finally it seems as if all the hard work is paying off. We've already developed better ways of diagnosing exposure to the infection, and now, with the success of creating a safe and effective vaccine, it looks as if we're finally bringing together the tools necessary to eradicate this terrible disease."
The vaccine consists of seven different Streptococcus proteins and results from early tests published in PLoS Pathogens have been incredibly positive showing a high level of protection and no side effects. It is hoped that the strangles vaccine could be commercially available in the near future.
Streptococcus equi, the bacterium that causes strangles, shares 80 per cent identity with Streptococcus pyogenes - the leading cause of bacterial pharyngitis, tonsillitis and rheumatic fever in humans, which kills thousands of people each year. Scientists hope that the knowledge gained through developing the strangles vaccine will also help in developing vaccines to combat these human conditions.
Research leader, Professor Bengt Guss of SLU, said: "This is a most exciting project, where research is generating new applications and knowledge that can be used to develop vaccines against these important bacteria. This is particularly important considering the increased number of infectious diseases caused by antibiotic-resistant bacteria."
The vaccine development work was only made possible thanks to information from the Streptococcus equi genome sequencing project funded by The Horse Trust.
The Horse Trust's Chief Executive Brigadier Paul Jepson, said: "We are absolutely delighted that by pulling apart the genome of this plague of the horse world scientists have generated a truly safe and effective strangles vaccine. That this work could also benefit other animal and human health is beyond our wildest hopes."
Full text of the research findings can be found in PLoS Pathogens online at http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1000584
Congratulations to VetSurgeon members Mike Martin, Malcolm Ness and Mark Patteson, who were amongst the winners of the 2010 BSAVA Annual Awards.
Mike Martin actually collected two awards this year: The Dunkin Award for the author of the most valuable article published in the Journal of Small Animal Practice (Canine dilated cardiomyopathy: a retrospective study of signalment, presentation and clinical findings in 369 cases), and the Blaine Award presented by Royal Canin for outstanding contributions to the advancement of small animal medicine or surgery.
Malcolm Ness won the Simon Award for outstanding contributions in the field of veterinary surgery.
Mark Patteson picked up the Melton Award, presented annually by Royal Canin for meritorious contributions by veterinary surgeons to small animal veterinary practice.
Other winners included Iona Mathieson (Frank Beattie Travel Scholarship), Anne Vaughan-Thomas (deceased) (Amoroso Award), David Church (Woodrow Award), Luke Gamble (J.A. Wright Memorial Award), Olaf Reinhard Schaaf (Petsavers Award) and Steve Withrow (Bourgelat Award).
Horiba Medical has announced it is the official exclusive UK distributor of the fully automated Vet abc Plus+ veterinary haematology analyser from scil animal care company GmbH, Germany.
According to the company, the compact Vet abc Plus+ provides a complete blood count (CBC), including 4-part white blood cell (WBC) differential, from only 10 µl of EDTA whole blood, in only 60 seconds.
The Vet abc Plus+ provides pre-installed settings to analyse samples from dogs, cats, horses, rabbits, mice, rats, cattle, pigs and sheep. For dogs, cats and horses, the Vet abc Plus+ provides a 4-part WBC differential blood count, including a differentiation of the leucocytes to identify lymphocytes, monocytes, granulocytes and eosinophils. Results are available in 60 seconds on screen or can be automatically printed out and transferred to the practice information system or clinical notes. For ease-of-use, the Vet abc Plus+ also incorporates a self-contained reagent and waste system which provides a clean operation whilst being easy to replenish.
Borne from an existing manufacturing partnership, scil and HORIBA Medical already have over 6000 veterinary haematology analysers placed globally. Horiba says the new UK distribution agreement enables UK veterinary professionals to not only procure the Vet abc Plus+ analyser, but also receive expert service and support directly from the manufacturer HORIBA Medical and its team of UK specialists.
For more information, visit: www.horiba.com/uk/medical